Journal of Hematology, ISSN 1927-1212 print, 1927-1220 online, Open Access |
Article copyright, the authors; Journal compilation copyright, J Hematol and Elmer Press Inc |
Journal website https://www.thejh.org |
Original Article
Volume 11, Number 1, February 2022, pages 8-14
Hematopoietic Stem Cell Transplantation Stabilizes Cerebral Vasculopathy in High-Risk Pediatric Sickle Cell Disease Patients: Evidence From a Referral Transplant Center
Figure
Tables
Values are provided as numbers (%) unless otherwise specified. HSCT: hematopoietic stem cell transplant. | |
Age at infusion, median (range), years | 10.6 (3.0 - 13.9) |
Gender | |
Female | 20 (80.0%) |
Male | 5 (20.0%) |
Sickle cell disease | |
SS | 22 (88.0%) |
Sβ0 | 3 (12.0%) |
Indications for HSCT | |
Cerebrovascular accident (n = 25) | |
Severe with moyamoya changes | 14 (56.0%) |
Moderate infarction | 7 (28.0%) |
Silent | 2 (8.0%) |
Transient | 2 (8.0%) |
Symptoms (symptomatic = 23, 92%) | |
Convulsions | 13 (52.0%) |
Hemiparesis | 11 (44.0%) |
Headache | 6 (24.0%) |
Psychiatric symptoms | 5 (20.0%) |
Focal neurological loss | 4 (16.0%) |
Loss of consciousness (any episode) | 2 (8.0%) |
Outcome of interest | Pre-HSCT, n (%) | Post-HSCT, n (%) | Improvement, n (%) | P value |
---|---|---|---|---|
aThe patient died after 6.5 months post-infusion due to exacerbation of chronic GVHD of gut. HSCT: hematopoietic stem cell transplant; GVHD: graft-versus-host disease; CV: cerebral vasculopathy. | ||||
Clinical findings pre- and post-HSCT | ||||
Hemiparesis | 11 (44.0%) | 1 (4.0%) | 10 (90.9%) | 0.002 |
Headache | 6 (24.0%) | 1 (4.0%) | 5 (83.3%) | 0.063 |
Psychological symptoms | 5 (20.0%) | 2 (8.0%) | 3 (60.0%) | 0.250 |
Focal neurological loss | 4 (16.0%) | 2 (8.0%) | 2 (50.0%) | 0.500 |
Loss of consciousness (any episode) | 2 (8.0%) | 1 (4.0%) | 1 (50.0%) | 1.000 |
Convulsions | 13 (52.0%) | 8 (32.0%) | 5 (38.5%) | 0.063 |
Post-HSCT radiological imaging results (n = 15) | ||||
Stabilized CV (alive) | 14 (93.3%) | |||
Stabilized CV (expired)a | 1 (6.1%) |